148 related articles for article (PubMed ID: 35065820)
1. Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in Beijing: A modeling analysis.
Zhu D; Lv M; Bai Y; Wu J; He P
Vaccine; 2022 Feb; 40(7):994-1000. PubMed ID: 35065820
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of quadrivalent versus trivalent influenza vaccine for elderly population in China.
Jiang M; Li P; Wang W; Zhao M; Atif N; Zhu S; Fang Y
Vaccine; 2020 Jan; 38(5):1057-1064. PubMed ID: 31787414
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model.
Yang MC; Tan EC; Su JJ
Hum Vaccin Immunother; 2017 Jan; 13(1):81-89. PubMed ID: 27624648
[TBL] [Abstract][Full Text] [Related]
4. [Cost-effectiveness analysis of quadrivalent influenza vaccination for older adults aged 60 and above in mainland China].
Yan H; Yang J; Chen ZY; Gong H; Zhong GJ; Yu HJ
Zhonghua Yi Xue Za Zhi; 2021 Aug; 101(30):2405-2412. PubMed ID: 34404135
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong - A decision analysis.
You JH; Ming WK; Chan PK
Hum Vaccin Immunother; 2015; 11(3):564-71. PubMed ID: 25714506
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States.
de Boer PT; Crépey P; Pitman RJ; Macabeo B; Chit A; Postma MJ
Value Health; 2016 Dec; 19(8):964-975. PubMed ID: 27987647
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy.
Mennini FS; Bini C; Marcellusi A; Rinaldi A; Franco E
Hum Vaccin Immunother; 2018; 14(8):1867-1873. PubMed ID: 29708843
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom.
Thommes EW; Ismaila A; Chit A; Meier G; Bauch CT
BMC Infect Dis; 2015 Oct; 15():465. PubMed ID: 26503131
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the U.K.
Meier G; Gregg M; Poulsen Nautrup B
J Med Econ; 2015; 18(9):746-61. PubMed ID: 25903831
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong.
You JH; Ming WK; Chan PK
BMC Infect Dis; 2014 Nov; 14():618. PubMed ID: 25420713
[TBL] [Abstract][Full Text] [Related]
11. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea.
Kim YK; Song JY; Jang H; Kim TH; Koo H; Varghese L; Han E
Pharmacoeconomics; 2018 Dec; 36(12):1475-1490. PubMed ID: 30251078
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme.
Bellier L; Petitjean A; Sarazu T; Tresierra J; Lopez JG
Vaccine; 2021 Jul; 39(30):4144-4152. PubMed ID: 34130885
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of different seasonal influenza vaccines in the elderly Italian population.
Capri S; Barbieri M; de Waure C; Boccalini S; Panatto D
Hum Vaccin Immunother; 2018 Jun; 14(6):1331-1341. PubMed ID: 29425079
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of quadrivalent influenza vaccine in Spain.
García A; Ortiz de Lejarazu R; Reina J; Callejo D; Cuervo J; Morano Larragueta R
Hum Vaccin Immunother; 2016 Sep; 12(9):2269-77. PubMed ID: 27184622
[TBL] [Abstract][Full Text] [Related]
15. The cost-effectiveness of trivalent and quadrivalent influenza vaccination in communities in South Africa, Vietnam and Australia.
de Boer PT; Kelso JK; Halder N; Nguyen TP; Moyes J; Cohen C; Barr IG; Postma MJ; Milne GJ
Vaccine; 2018 Feb; 36(7):997-1007. PubMed ID: 29373192
[TBL] [Abstract][Full Text] [Related]
16. Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis.
Bianculli PM; Bellier L; Mangado IO; Pérez CG; Mieres G; Lazarov L; Petitjean A; Dibarboure H; Lopez JG
Hum Vaccin Immunother; 2022 Nov; 18(5):2050653. PubMed ID: 35344679
[TBL] [Abstract][Full Text] [Related]
17. Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey.
Amiche A; Tanriover MD; Bellier L; Ugur B; Akin L
Value Health Reg Issues; 2021 Sep; 25():15-22. PubMed ID: 33485248
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effective analysis of seasonal influenza vaccine in elderly Chinese population].
Chen C; Liu GE; Wang MJ; Gao TF; Jia HP; Yang H; Feng LZ
Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Oct; 53(10):993-999. PubMed ID: 31607044
[No Abstract] [Full Text] [Related]
19. Cost Effectiveness of Quadrivalent Versus Trivalent Inactivated Influenza Vaccines for the Portuguese Elderly Population.
Tavares D; Mouriño H; Rodríguez CA; Saborido CM
Vaccines (Basel); 2022 Aug; 10(8):. PubMed ID: 36016173
[TBL] [Abstract][Full Text] [Related]
20. Cost effectiveness of trivalent and quadrivalent influenza vaccines in 50- to 64-year-old adults in Korea.
Choi EJ; Park JH; Chun BC
Vaccine; 2020 Jul; 38(32):5002-5008. PubMed ID: 32532543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
